News of Note—Sanofi, Dynavax and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> The FDA approved an expanded use for Sanofi's Tdap vaccine Adacel to allow for repeat vaccinations. Release

> Dynavax predicts an "inflection point" in sales for its Heplisav-B vaccine and that the vaccine will be profitable by the end of 2019. Presentation

> The Coalition for Epidemic Preparedness Innovations (CEPI) tapped the University of Queensland in a deal worth up to $10.6 million to develop a “molecular clamp” vaccine platform, which enables rapid vaccine production against multiple viral pathogens. Release

> Univercells launched its low-cost vaccine production system, NevoLine, triggering a $4 million grant extension from the Bill & Melinda Gates Foundation to scale up the platform. Release

Read more on

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.